(0.13%) 5 187.70 points
(0.08%) 38 884 points
(-0.10%) 16 333 points
(-0.14%) $78.37
(1.14%) $2.22
(-0.39%) $2 322.20
(-0.47%) $27.49
(2.41%) $988.20
(0.17%) $0.930
(0.67%) $10.90
(0.44%) $0.799
(0.22%) $91.54
Quarter results today
(bmo 2024-05-07)
Expected move: +/- 4.36%
@ $15.84
जारी किया गया: 15 Feb 2024 @ 01:47
वापसी: -1.96%
पिछला सिग्नल: Feb 14 - 23:56
पिछला सिग्नल:
वापसी: 0.54 %
Live Chart Being Loaded With Signals
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA...
Stats | |
---|---|
आज की मात्रा | 385 342 |
औसत मात्रा | 713 250 |
बाजार मूल्य | 970.91M |
EPS | $0 ( 2024-02-27 ) |
अगली कमाई की तारीख | ( $0.170 ) 2024-05-14 |
Last Dividend | $0.250 ( 2015-09-08 ) |
Next Dividend | $0 ( N/A ) |
P/E | 7.06 |
ATR14 | $0.00600 (0.04%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-29 | Small Derek A | Sell | 1 206 | Restricted Stock Units |
2024-04-29 | Small Derek A | Sell | 833 | Stock Options |
2024-03-05 | Basso Stephen | Buy | 25 899 | Non-statutory Stock Option |
2024-03-05 | Basso Stephen | Buy | 12 096 | Common Stock |
2024-03-05 | Ronsheim Matthew | Buy | 27 338 | Non-statutory Stock Option |
INSIDER POWER |
---|
89.35 |
Last 96 transactions |
Buy: 2 118 652 | Sell: 32 095 513 |
मात्रा सहसंबंध
Innoviva Inc सहसंबंध
10 सबसे अधिक सकारात्मक सहसंबंध | |
---|---|
ONEM | 0.92 |
ESSA | 0.92 |
NAKD | 0.911 |
AADI | 0.909 |
AROW | 0.908 |
DSWL | 0.906 |
AZTA | 0.905 |
BSRR | 0.904 |
UK | 0.902 |
SRDX | 0.897 |
10 सबसे अधिक नकारात्मक सहसंबंध | |
---|---|
NEO | -0.927 |
TMDX | -0.919 |
MORF | -0.916 |
ACVA | -0.913 |
SGTX | -0.911 |
SJ | -0.909 |
MHUA | -0.909 |
MYNA | -0.907 |
RMRM | -0.907 |
MLTX | -0.904 |
क्या आप जानते हैं?
कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।
कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।
Innoviva Inc सहसंबंध - मुद्रा/वस्त्र
Innoviva Inc वित्तीय
Annual | 2023 |
राजस्व: | $324.26M |
सकल लाभ: | $245.92M (75.84 %) |
EPS: | $-1.910 |
FY | 2023 |
राजस्व: | $324.26M |
सकल लाभ: | $245.92M (75.84 %) |
EPS: | $-1.910 |
FY | 2022 |
राजस्व: | $331.34M |
सकल लाभ: | $317.55M (95.84 %) |
EPS: | $-1.080 |
FY | 2021 |
राजस्व: | $391.87M |
सकल लाभ: | $0.00 (0.00 %) |
EPS: | $2.62 |
Financial Reports:
No articles found.
Innoviva Inc Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
First Dividend | $0.250 | 2014-08-26 |
Last Dividend | $0.250 | 2015-09-08 |
Next Dividend | $0 | N/A |
Payout Date | 2015-09-30 | |
Next Payout Date | N/A | |
# dividends | 5 | -- |
Total Paid Out | $1.250 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.77 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 3.68 | |
Div. Directional Score | 7.39 | -- |
Year | Amount | Yield |
---|---|---|
2014 | $0.500 | 1.84% |
2015 | $0.750 | 5.65% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0 | 0.00% |
2022 | $0 | 0.00% |
2023 | $0 | 0.00% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.573 | 1.500 | 10.00 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.145 | 1.200 | 5.18 | 6.22 | [0 - 0.3] |
returnOnEquityTTM | 0.297 | 1.500 | 7.81 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 9.03 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 7.28 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 5.07 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.360 | -1.500 | 4.00 | -6.00 | [0 - 0.6] |
interestCoverageTTM | 9.70 | 1.000 | 7.52 | 7.52 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.21 | 2.00 | 9.26 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 2.21 | 2.00 | 8.90 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.663 | -1.500 | 7.35 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.832 | 1.000 | 10.00 | 10.00 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.592 | 1.000 | 0.162 | 0.162 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.315 | 1.000 | 9.36 | 9.36 | [0.2 - 2] |
assetTurnoverTTM | 0.252 | 0.800 | -1.650 | -1.320 | [0.5 - 2] |
Total Score | 11.10 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 5.48 | 1.000 | 9.55 | 0 | [1 - 100] |
returnOnEquityTTM | 0.297 | 2.50 | 8.59 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 2.21 | 2.00 | 9.26 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0 | 1.500 | 0 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.21 | 2.00 | 9.26 | 10.00 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0.103 | 1.500 | -2.64 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.449 | 1.000 | 1.265 | 0 | [0.1 - 0.5] |
Total Score | 3.68 |
Innoviva Inc
Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA, and VI; and TRELEGY ELLIPTA, a once-daily combination medicine consisting of an ICS, LAMA, and LABA. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. The company has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
के बारे में लाइव सिग्नल्स
इस पृष्ठ पर प्रस्तुत लाइव सिग्नल्स NA को कब खरीदना या बेचना है, इसका निर्धारण करने में मदद करते हैं। सिग्नल्स में 1-मिनट की देरी हो सकती है; सभी बाजार सिग्नल्स की तरह, त्रुटि या गलतियों की संभावना होती है।
लाइव ट्रेडिंग सिग्नल्स स्थायी नहीं हैं, और getagraph.com इन सिग्नल्स पर किए गए किसी भी कार्रवाई के लिए जिम्मेदारी नहीं रखते हैं, जैसा कि उपयोग की शर्तें में वर्णित है। सिग्नल्स एक व्यापक श्रृंखला के तकनीकी विश्लेषण संकेतकों पर आधारित हैं